Many people with this disease are first treated for uveitis, an inflammation inside the eye, often for months. Vitreoretinal lymphoma is a rare cancer of lymphocytes, a type of white blood cell. It grows in the retina, the light-sensing layer at the back of the eye, and in the vitreous, the clear gel that fills the eye. Its first signs, floaters and misty vision, look very much like uveitis.
A small sample from inside the eye confirms the diagnosis, and eye treatment usually works. The main concern is the brain, so eye care and cancer care are planned together. The disease is also called primary intraocular lymphoma or ocular lymphoma. Other eye cancers are described in our eye cancer guide.
What is vitreoretinal lymphoma?
Most cases are primary vitreoretinal lymphoma: a lymphoma of the brain and spinal cord (primary central nervous system lymphoma) that shows up first in the eye. The retina develops as an outgrowth of the brain, and the two stay closely linked. In published series, 35–90% of patients develop lymphoma in the brain or spinal fluid at some point. Almost all cases are diffuse large B-cell lymphoma, a fast-growing type. Other forms of eye lymphoma behave differently:
| Form | Where it grows | Usual type |
|---|---|---|
| Primary vitreoretinal lymphoma | Retina and vitreous; linked with brain lymphoma | Diffuse large B-cell lymphoma |
| Uveal (choroidal) lymphoma | Choroid, the blood-vessel layer under the retina | Usually slow-growing (low-grade) marginal zone lymphoma |
| Secondary ocular lymphoma | The eye, from a lymphoma that began elsewhere in the body | Depends on the original lymphoma |
| Ocular adnexal lymphoma | Conjunctiva, orbit, eyelid, tear gland or tear sac | Mostly slow-growing marginal zone (MALT) lymphoma |
Who gets it?
Vitreoretinal lymphoma makes up less than 1% of all tumors inside the eye. It is usually found in middle or later adult life and slightly more often in women. In 80–90% of patients both eyes are affected sooner or later. It is not contagious and not inherited.
What are the symptoms, and why is it called a masquerade syndrome?
A masquerade syndrome is a disease, often a cancer, that imitates ordinary inflammation. Vitreoretinal lymphoma is a typical example. Its usual symptoms are:
- Floaters (spots or cobwebs drifting across your vision)
- Blurred or hazy vision, frequently in both eyes
- Often little pain or redness, unlike many types of uveitis
At the examination, the specialist sees cells floating in the vitreous and sometimes yellowish patches under the retina. Steroid drops, tablets or injections may seem to help for a while, but the haze comes back.
How is vitreoretinal lymphoma diagnosed?
Optical coherence tomography (OCT), a detailed scan of the retina, and other scans can show deposits in or under the retina. Confirming the diagnosis, however, requires a test of fluid from inside the eye:
- Examination and scans of both eyes, with a review of earlier treatment, especially how the eyes responded to steroids.
- Vitreous biopsy (diagnostic vitrectomy): a short operation to take a sample of the vitreous gel, planned so that several tests can be run on a small amount.
- Laboratory tests on the sample (see the table below).
- Staging: a brain MRI with contrast and a lumbar puncture (a sample of the fluid around the spinal cord), arranged with the hematology-oncology team, who may add other tests.
- A joint treatment plan agreed by the eye specialist and the lymphoma team.
| Test | What it shows | Why it matters |
|---|---|---|
| Cytology | Lymphoma cells under the microscope | Confirms the diagnosis, but on its own gives a clear answer in only about half of samples (around 48%) |
| Flow cytometry and gene rearrangement tests | A single "clone" of B cells | Points to lymphoma rather than inflammation |
| MYD88 L265P mutation | A gene change found in up to about 87% of cases | Adds certainty when cytology is unclear |
| IL-10/IL-6 ratio | The balance of two signaling proteins (interleukins 10 and 6) | A ratio above 1 suggests lymphoma; inflammation usually gives a ratio below 1 |
Steroids can make lymphoma cells harder to find. Your specialist may therefore advise on the timing of steroids before the biopsy; never stop a prescribed medicine on your own. See also how eye tumors are diagnosed.
How is intraocular lymphoma treated?
Treatment has three aims: clear the lymphoma from the eye, protect sight, and control disease in the brain and body or watch for it. The ocular oncologist plans the eye treatment; hematology-oncology specialists plan the rest.
| Treatment | How it is given | When it is used | Points to know |
|---|---|---|---|
| Methotrexate injections into the eye (intravitreal) | A series of small injections over months | Usual first choice for the eye | About 98.5% of eyes cleared completely on an optimized schedule |
| Rituximab injections into the eye | An antibody that targets B cells | If methotrexate is not tolerated or does not work | Complete clearing in about 65% when used alone |
| Radiotherapy to the eyes | External beam, over several sessions | Both eyes affected, or a poor response to injections | Planned by radiation oncology |
| Systemic treatment | Chemotherapy, usually based on high-dose methotrexate | Lymphoma in the brain or body | Given by hematology-oncology |
The optimized methotrexate schedule, described in 2024, runs as follows:
Methotrexate injections into the eye
First 4 weeks
Weekly injections.
Next 2 months
An injection every 2 weeks.
Following 6–12 months
Monthly injections.
The main side effect is irritation of the corneal surface (keratopathy): it occurred in about 10% of eyes, compared with 20–30% on older schedules. Whether lymphoma confined to the eyes also needs systemic treatment is still debated; this is decided with the lymphoma team.
What is the outlook?
The outlook depends mainly on whether the brain becomes involved. Eye treatment usually works, but lymphoma can return in either eye or appear in the brain later. Follow-up with eye examinations and regular brain MRI is therefore lifelong.
In primary central nervous system lymphoma, survival has improved from about 1 year in the past to more than 3 years with modern chemotherapy. It also depends on the molecular subtype of the lymphoma. About 70% of patients with the "germinal center" type were free of disease at 5 years, compared with about 30% with the "activated B-cell" type. These are figures for large groups; your hematologist-oncologist can explain what they mean for you. See also Is eye cancer curable?
What is lymphoma around the eye (the "salmon patch")?
Lymphoma can also grow around the eyeball: in the conjunctiva (the thin membrane over the white of the eye), the orbit, the eyelid, the tear gland or the tear sac. This is called ocular adnexal lymphoma. Most cases are slow-growing marginal zone lymphomas, also called MALT lymphomas (from mucosa-associated lymphoid tissue). On the conjunctiva it typically forms a smooth, salmon-pink patch, often in the fold between the eyelid and the eyeball. The patch usually does not hurt. A biopsy is essential, because a harmless overgrowth of lymphoid tissue (reactive lymphoid hyperplasia) can look identical.
In a Wills Eye series, lymphoma elsewhere in the body was found in 17% of patients with a conjunctival tumor in one eye. When both eyes were affected, the figure was 47%. That is why staging with the hematology team follows. Localized disease is usually treated with low-dose radiotherapy, increasingly with a very low total dose of 4 Gy (gray, the unit of radiation dose). Rituximab, doxycycline for selected cases and chemoimmunotherapy for widespread disease are alternatives. With the marginal zone type, about 97% of patients had not died of their lymphoma 5 years later. See conjunctival tumors and orbital tumors.
Can leukemia affect the eye?
Leukemia, a cancer of the blood-forming cells, can occasionally spread into eye tissues, including the iris (the colored part of the eye). A detailed scan of the front of the eye, anterior segment OCT, can record such changes. Prof. Dr. Elif Betül Türkoğlu has published on this topic. If you are being treated for leukemia and notice a change in how an eye looks, pain or blurred vision, tell your hematology team and arrange an eye examination.
Diagnosis and treatment planning in Antalya
This disease sits between eye care and cancer care. Prof. Türkoğlu evaluates the eye findings and the course of the "uveitis," plans the diagnostic steps including the biopsy, and follows the eye's response to treatment. Brain imaging, spinal fluid tests and systemic treatment are organized with hematology-oncology specialists.
If you live abroad, start with a remote second opinion based on your scans and reports. Injections continue for months, so part of the treatment may be carried out by doctors near your home; this is decided case by case. See also international patients and our page for referring doctors.
Frequently asked questions
Is vitreoretinal lymphoma the same as uveitis?
No. Uveitis is inflammation inside the eye; vitreoretinal lymphoma is a cancer of white blood cells that can look very similar. Suspicion rises when "uveitis" starts in an adult, often over 50, affects both eyes, keeps coming back or does not improve with steroids. Only a sample of the vitreous can tell the two apart with confidence.
Is the vitreous biopsy safe?
Generally, yes. It is a standard operation with the usual risks of eye surgery. The biopsy is a vitrectomy, done through very small openings in the white of the eye. Infection, bleeding or retinal detachment are possible, and your surgeon explains these risks beforehand. The handling of the small sample is planned so that all key tests can be run.
Will the lymphoma spread to my brain?
It may. In published series, 35–90% of people with vitreoretinal lymphoma develop lymphoma in the brain or spinal fluid at some point. A brain MRI and a spinal fluid test are therefore part of the first tests. Brain MRI is then repeated during follow-up, so that any spread is found early.
What are the side effects of methotrexate injections?
The most common is irritation of the corneal surface (keratopathy). It affected about 10% of eyes on the optimized 2024 schedule, compared with 20–30% on older schedules. Your specialist checks the cornea at each visit. If methotrexate is not tolerated, the schedule can be adjusted or rituximab considered.
Do I need chemotherapy or radiotherapy?
It depends on where the lymphoma is found. If the brain or body is involved, the hematology-oncology team gives systemic chemotherapy, usually based on high-dose methotrexate. If the disease is limited to the eyes, treatment focuses on injections into the eye. Radiotherapy to the eyes is an option when both eyes are affected or injections are not enough.
Can vitreoretinal lymphoma come back?
Yes. It can return in the treated eye, in the other eye or in the brain. Follow-up therefore continues for life, with regular eye examinations and periodic brain MRI. Between visits, report any new floaters, blurred vision or neurological symptoms promptly.
Is a salmon-pink patch on the eye a lymphoma?
It can be. A smooth, salmon-pink patch on the white of the eye that does not hurt is typical of lymphoma of the conjunctiva. A harmless overgrowth of lymphoid tissue can look exactly the same, so only a biopsy gives the answer. If it is lymphoma, staging with the hematology team follows; localized disease is usually treated with low-dose radiotherapy.
References
- EyeWiki (American Academy of Ophthalmology). Primary Vitreoretinal Lymphoma. eyewiki.org
- EyeWiki (American Academy of Ophthalmology). Conjunctival Lymphoma. eyewiki.org
- Shields CL, et al. [Review of 5,002 conjunctival tumors: clinical features, risks, biomarkers and outcomes]. Asia-Pacific Journal of Ophthalmology, 2017. journals.lww.com
- Grujić et al. [Systematic review of ultra-low-dose (2 × 2 Gy) radiotherapy for indolent ocular adnexal lymphoma]. Cancers, 2025. PMC
- Min et al. [Treatment outcomes in 292 patients with ocular adnexal MALT lymphoma]. Frontiers in Oncology, 2022. frontiersin.org
- Türkoğlu EB, Öcal O. Anterior segment optical coherence tomography findings in leukemic iris infiltration. Photodiagnosis and Photodynamic Therapy, 2022;37:102578. PubMed
